Patents by Inventor Antje A. Winsemius

Antje A. Winsemius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110070319
    Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 24, 2011
    Inventors: Michel BOURIN, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen
  • Publication number: 20090068290
    Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 12, 2009
    Inventors: Michel Bourin, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen
  • Publication number: 20080132520
    Abstract: The present disclosure is directed to a composition regimen, a titration kit, and methods of administration to facilitate the initiation of the treatment of at least one central nervous system condition or disorder by administering a plurality of dosage units of at least one bifeprunox compound, such as 7-[4-([1,1?-biphenyl]-3-ylmethyl)-1-piperazinyl ]-2(3H)-benzoxazolone (INN bifeprunox), according to a titration schedule.
    Type: Application
    Filed: August 29, 2007
    Publication date: June 5, 2008
    Inventors: Antje A. Winsemius, Pieter W.A.J. Van Den Broeck, Luigi M. Barbato